24 Oct 2018 07:00
Destiny Pharma plc
("Destiny Pharma" or the "Company")
Â
Destiny Pharma's lead asset, XF-73, well positioned to address the global threat of anti-microbial resistance highlighted in new UK government report
Â
Brighton, United Kingdom - 24 October 2018 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), welcomes a recent report from the UK government's health and social care committee focusing on the global threat of AMR and the urgent need for new treatments to tackle infections.
Â
Destiny Pharma's novel drug candidate, XF-73, is currently in Phase II clinical development and is designed to deliver a profile that specifically targets the prevention of post-surgical infections, such as methicillin-resistant Staphylococcus aureus (MRSA). Unlike most antibiotics, XF-73 has not been seen to generate bacterial resistance in industry-standard microbiology tests to date and therefore also has significant potential to address the global threat of AMR alongside its fast, safe and effective anti-infective action.
Â
Neil Clark, Chief Executive Officer of Destiny Pharma, commented:
"If we are successful in the development of our lead asset, XF-73 will be a novel drug to prevent post-surgical infections with the profile required to meet the AMR challenges highlighted by the UK government this week. We remain well-funded through to H2 2020 as we seeks to address this global issue, estimated in the US alone to be a $1 billion sales opportunity."
Â
The full report from the UK government's health and social care committee can be found here.
Â
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
pressoffice@destinypharma.comÂ
+44 (0)1273 704 440
Â
FTI Consulting
Simon Conway / Victoria Foster Mitchell
destinypharma@fticonsulting.comÂ
+44 (0) 20 3727 1000
Â
Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker)
Philip Davies / Will Goode, Corporate Finance
Andrew Keith, Healthcare Equity Sales
+44 (0)20 7894 7000
Â
finnCap Ltd (Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
Â
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the World Health Organisation (WHO) and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.comÂ